Cerebrospinal Fluid CHI3L2 as a Biomarker for Amyotrophic Lateral Sclerosis and Predicts Faster Disability Progression

Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS